Thromboelastography to Monitor Clotting/Bleeding Complications in Patients Treated with the Molecular Adsorbent Recirculating System
Figure 4
Clotting parameters deteriorate during MARS therapy: (a) Evolution of the clotting parameters INR, aPTT, TT, plasma fibrinogen concentration, D-Dimer, platelet count and the thromboelastography parameters CT, CFT, MCF and Lys 60′ during MARS therapy. Each line represents a pair of values from an individual MARS treatment session. Gray dots represent values from uneventful MARS session, black open circles sessions complicated by device clotting and black triangles sessions with bleeding complications. Closed black circles connected by a thick black line indicate mean values. All parameters worsened significantly during MARS sessions, values are indicated, to 25. (b) and (c) Sessions of MARS therapy were split up into 3 subgroups, uneventful sessions (eventless, ), sessions with bleeding complications (bleeding, ) and sessions complicated by device clotting (clotting, ). For each individual session the value obtained at around 2 h of MARS therapy was subtracted from the baseline value. For each parameter, the differences were compared between subgroups by ANOVA and in case of significance Bonferroni group comparison was performed. ANOVA was only significant for the parameter TT (b) and Lys 60′ (c). *Indicates significantly different subgroups at the level, (b) and 13 (c), respectively.
